EMA provides drug-naming guide; Novartis withdraws Gleevec app in EU for hypertension;

@FiercePharma: Merrill Lynch high on Bayer: The company made its list of top Euro-stocks, thanks to new drugs/pipeline. More | Follow @FiercePharma

 @AlisonBFierce: Feds OK Novavax's experimental flu vaccine program. News | Follow @AlisonBFierce

> Generic drugmaker Dr. Reddy's Laboratories has launched generic antihistamine desloratadine tablets in the U.S., a bioequivalent generic version of Schering Clarinex Reditabs tablets. Item

> FDA staff said they didn't believe Boehringer Ingelheim's once-daily drug for chronic obstructive pulmonary disease offered significant benefits. Story

> Net income at Procter & Gamble ($PG) more than doubled to $4.06 billion in the last quarter. Story

> Bank of America Merrill Lynch put German Bayer on its list of top European stocks, citing confidence in its drug pipeline and agriculture unit. Story

> The European Medicines Agency has lined out its thoughts on naming branded drugs in an update of one of its documents. Item

> The FDA today approved Oxytrol for women, the first over-the-counter treatment for overactive bladder in women ages 18 and older. Release

Medical Device News

 @FierceMedDev: Spiking costs blunt Covidien's strong sales quarter. News | Follow @FierceMedDev

 @DamianFierce: Dx company LipoScience is going public, targeting a $40M IPO as $LPDX. Report | Follow @DamianFierce

> ResMed posts 24% income jump in another big quarter. Article

> iRobot spikes on the Street after FDA OK. Story

Biotech News

 @FierceBiotech: AstraZeneca kicks tires on respiratory program ditched by J&J. Story | Follow @FierceBiotech

@JohnCFierce: Cowen's Ed Nash is predicting '16 arrival of Sarepta's eteplirsen, with $263M start Question about accelerated OK. Personally I'm doubtful. | Follow @JohnCFierce

@RyanMFierce: IBM touts push into #biotech with bug-busting gel. Should we care yet? Report | Follow @RyanMFierce

> Celsion snags up to $100M Chinese pharma tie-up ahead of PhIII cancer data. Article

> What's in a drug name? Hopefully some Xzitement. News

And Finally... Novartis ($NVS) has withdrawn a marketing application to get approval in Europe for its cancer blockbuster Glivec/Gleevec, as a treatment for pulmonary arterial hypertension. Release

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.